Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma: a multi-institutional study

Suzuki Takashi, Yajima Satoshi, Okamura Akihiko, Yoshida Naoya, Taniyama Yusuke, Murakami Kentaro, Ohkura Yu, Nakajima Yasuaki, Yagi Koichi, Fukuda Takashi, Ogawa Ryo, Hoshino Isamu, Kunisaki Chikara, Narumiya Kosuke, Tsubosa Yasuhiro, Yamada Kazuhiko, Shimada Hideaki

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Although the clinicopathological significance of serum p53 antibodies (s-p53-Abs) in esophageal cancer have been evaluated previously, previous reports only analyzed around 100–200 patients. This study was a multi-institutional study promoted by the Japan Esophageal Society to evaluate the clinical significance of preoperative s-p53-Ab status and antibody titers in 1487 esophageal cancer patients without neoadjuvant therapy. Methods: A total of 1487 patients with esophageal squamous cell carcinoma surgically treated between 2008 and 2016 in 15 hospitals in Japan were enrolled. The cut-off value to classify the patients into s-p53-Ab positive and negative groups was 1.30 U/ml. A receiver operating characteristic curve was constructed to assess the s-p53-Abs cut-off levels to differentiate poor prognosis among the s-p53-Ab positive group. Univariate and multivariate analyses were used to evaluate the clinicopathological and prognostic significance of s-p53-Ab status and titers. Results: Although s-p53-Ab status was significantly associated with tumor depth (P = 0.002), nodal status (P = 0.027), and pathological stage (P = 0.002). The s-p53-Ab positive status was not significantly associated with poor overall survival (P = 0.699). Using 9.82 U/ml as a cut-off, the high s-p53-Ab titer group showed a significantly worse overall survival than the low s-p53-Ab titer group (P = 0.038). However, the difference was not significant in the multivariate analysis. Conclusion: The presence of s-p53-Abs was associated with tumor progression. Although high s-p53-Ab titers more than 9.82 U/ml, might be associated with poor prognosis for patients with esophageal squamous cell carcinoma, it was not an independent risk factor.

Original languageEnglish
Pages (from-to)65-71
Number of pages7
JournalEsophagus
Volume18
Issue number1
DOIs
Publication statusPublished - 2021 Jan
Externally publishedYes

Keywords

  • Antibody titers
  • Esophageal squamous cell carcinoma
  • Prognosis
  • Serum p53 antibodies

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma: a multi-institutional study'. Together they form a unique fingerprint.

Cite this